FDA Recommends Genetic Testing For Plavix Response, Opens Window For Effient
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA increased the level of its Plavix warning for slow metabolizers to a black box, recommending genetic testing and advising health care professionals to consider using other anti-platelet medications or alternative dosing strategies.